PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or its ligand (PD-L1) as monotherapy or in combination with chemotherapy have transformed the treatment landscape for patients with metastatic NSCLC, especially those without oncogenic driver mutations [6–11].